Radotinib as 3rd or Later Line Therapy in CP-CML

Clinical trial NCT02422719 · UNKNOWN

Trial details

NCT number: NCT02422719
Sponsor: Ulsan University Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Myeloid Leukemia

Start date: 2015-04-01
Primary completion: 2019-03-01
Enrollment: 73

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.